MedTrace Logo

Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects

NCT02750384 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-09-14

No results posted yet for this study

Summary

This is a single-dose, fasting and non-fasting, open-label, randomized, three-regimen, parallel group study in 42 subjects

Conditions

  • Healthy Volunteers
  • Bioavailability

Interventions

DRUG

DSM265 50% SDD granules

Single oral dose 400 mg

DRUG

DSM265 25% SDD powder for suspension

Single oral dose 400 mg

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • David, Carter, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02750384 on ClinicalTrials.gov